Please login to the form below

Not currently logged in
Email:
Password:

Therachon appoints new chief medical officer

Dr Maarten Kraan joins the company from AstraZeneca

Dr Maarten KraanBasel, Switzerland-based biotech company Therachon has appointed Dr Maarten Kraan as its new chief medical officer in a role that will see him focus on the clinical development of TA-46 - Therachon’s leading drug in development for achondroplasia.

Kraan has held numerous roles such as vice president, immunosciences at Bristol-Myers Squibb, vice president, head of clinical research and experimental development at Roche, and most recently as head of innovative medicines respiratory and inflammation at AstraZeneca.

Luca Santarelli, chief medical officer at Therachon, said: “Dr Kraan’s wealth of translational and drug development expertise is critical during this exciting time in our company’s growth. He will play a key role in guiding TA-46 from discovery into clinical development and helping us fulfill our mission of developing medicines for rare, genetic diseases.”

In addition to his new role Dr Kraan will continue to serve as an adjunct professor at Goteborg University in Sweden.

27th March 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
TRIDUCIVE

Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...

Latest intelligence

Ask the writers: Transitioning from academia to medical writing
Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
Strategic launch planning: familiar framework, new mindset
By James Aird...
Guide
How to embrace behavioural science principles in healthcare MR...